J. Abraham

发表

FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.

E. Maiello, A. Zaniboni, D. Rossini, 2022, European journal of cancer.

Pan-cancer analysis of RNA expression of ANGIOTENSIN-CONVERTING ENZYME II (ACE2) and cellular proteases reveals high variability and possible impact on COVID-19 clinical outcomes

P. Stafford, H. Lenz, D. Spetzler, 2020 .

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing

B. Halmos, S. Dacic, P. Ma, 2022, JTO clinical and research reports.

Immune evasion in HPV− head and neck precancer–cancer transition is driven by an aneuploid switch involving chromosome 9p loss

S. Lippman, H. Carter, L. Alexandrov, 2021, Proceedings of the National Academy of Sciences.

Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type

M. Oberley, P. Stafford, E. Heath, 2021, Translational oncology.

Response to “The need for validation of MI GPSai in patients with CUP: Comment on: “Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type” by J Abraham et al.“

M. Oberley, C. Nabhan, W. Korn, 2021, Translational oncology.

Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer

D. Berry, M. Oberley, P. Stafford, 2020, Clinical Cancer Research.

Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes

Edward S. Kim, P. Stafford, H. Lenz, 2021, Scientific Reports.

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.

M. Oberley, P. Stafford, H. Lenz, 2021, Journal of the National Cancer Institute.

Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer

P. Stafford, R. Goldberg, H. Lenz, 2021, Oncogene.

Discoidin domain receptor-driven gene signatures as markers of patient response to anti-PD-L1 immune checkpoint therapy.

M. Galsky, D. Theodorescu, K. Chan, 2022, Journal of the National Cancer Institute.

Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.

M. Oberley, G. Fontanini, H. Lenz, 2021, European Journal of Cancer.

Somatic 9p24.1 alterations in HPV– head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity

S. Lippman, L. Alexandrov, W. Cavenee, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Pan-sarcoma analysis of DNA damage response pathway alterations and deficiency.

M. von Mehren, J. Trent, G. D'Amato, 2022, Journal of Clinical Oncology.

Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in >28,000 colorectal tumors.

M. Oberley, E. Antonarakis, J. Swensen, 2023, Journal of Clinical Oncology.

CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value

Taline Khoukaz, A. Venook, J. Millstein, 2024, Journal for immunotherapy of cancer.